Spots Global Cancer Trial Database for hematologic cancers
Every month we try and update this database with for hematologic cancers cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cognitive Training Intervention and Attitudes Towards Genetics | NCT03094026 | Cognitive Impai... Hematologic Neo... Hematopoietic C... | Lumosity Lumosity (waitl... | 21 Years - | University of Alabama at Birmingham | |
| A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes | NCT02848001 | Leukemia, Myelo... Myelodysplastic... | CC-90009 | 18 Years - | Celgene | |
| A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes | NCT02848001 | Leukemia, Myelo... Myelodysplastic... | CC-90009 | 18 Years - | Celgene | |
| A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | NCT02367196 | Hematologic Neo... | CC-90002 Rituximab | 18 Years - | Celgene | |
| A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia | NCT00964873 | Acute Myeloid L... Acute Lymphobla... Blast-phase Chr... AML ALL CML | STA-9090 (ganet... | 18 Years - | Synta Pharmaceuticals Corp. | |
| Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | NCT03512340 | Advanced Solid ... Hematologic Can... | SRF231 | 18 Years - 99 Years | Surface Oncology | |
| A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia | NCT04336982 | Leukemia, Myelo... | CC-90009 Venetoclax Azacitidine Gilteritinib | 18 Years - | Celgene | |
| A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes | NCT02848001 | Leukemia, Myelo... Myelodysplastic... | CC-90009 | 18 Years - | Celgene | |
| Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | NCT03512340 | Advanced Solid ... Hematologic Can... | SRF231 | 18 Years - 99 Years | Surface Oncology | |
| Genomic Profiling in Cancer Patients | NCT01775072 | Solid Tumors Hematologic Can... | molecular profi... Clinical Germli... | - | Memorial Sloan Kettering Cancer Center | |
| Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations | NCT02304809 | Solid Tumors Hematologic Can... Metastatic Canc... | Vemurafenib | 18 Years - | UNICANCER | |
| A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | NCT02367196 | Hematologic Neo... | CC-90002 Rituximab | 18 Years - | Celgene | |
| Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | NCT03512340 | Advanced Solid ... Hematologic Can... | SRF231 | 18 Years - 99 Years | Surface Oncology |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
